Genyzme Reports Manufacturing Problems For Drug Used To Treat Rare Disorder

The Cambridge-based bio-tech giant Genzyme is reporting new manufacturing problems at its Allston plant. Citing what they call 'environmental monitoring findings,' Genzyme officials say they've rejected a batch of the drug Fabrazyme, used to treat a rare genetic disorder.

The company is not saying what those findings are, but it is acknowledging some patients who take the drug may miss one or more doses over the next few months.

Many patients who take Fabrazyme are already on half-doses, due to production concerns that forced the plant to close two years ago.

Some patients have reported symptoms like fatigue and digestive problems since then, and are worried missing doses may make those problems even worse.